Citi initiated coverage of Sanofi (SNY) with a Neutral rating and EUR 85 price target The firm believes the company’s pipeline will be unable to address its growth challenges post the Dupixent loss of exclusivity.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi SA (SNY) Q4 Earnings Cheat Sheet
- Apogee selloff on Sanofi data brings opportunity, says UBS
- Apogee Therapeutics selloff on Sanofi data overdone, says Citi
- Sanofi Advances Amlitelimab Toward Global Filings After Positive Phase 3 Atopic Dermatitis Data
- Moderna Stock (MRNA) Hits a New 52-Week High — Can the Rally Last Through 2026?